These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33808897)

  • 1. Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics.
    Lima AR; Pinto J; Amaro F; Bastos ML; Carvalho M; Guedes de Pinho P
    Metabolites; 2021 Mar; 11(3):. PubMed ID: 33808897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMR-based metabolomics studies of human prostate cancer tissue.
    Lima AR; Pinto J; Bastos ML; Carvalho M; Guedes de Pinho P
    Metabolomics; 2018 Jun; 14(7):88. PubMed ID: 30830350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of patients with and without prostate cancer using urine
    Hasubek AL; Wang X; Zhang E; Kobus M; Chen J; Vandergrift LA; Kurreck A; Ehret F; Dinges S; Hohm A; Tilgner M; Buko A; Habbel P; Nowak J; Mercaldo ND; Gusev A; Feldman AS; Cheng LL
    Magn Reson Chem; 2023 Dec; 61(12):740-747. PubMed ID: 37654196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker Discovery in Human Prostate Cancer: an Update in Metabolomics Studies.
    Lima AR; Bastos Mde L; Carvalho M; Guedes de Pinho P
    Transl Oncol; 2016 Aug; 9(4):357-70. PubMed ID: 27567960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating metabolite biomarkers: a game changer in the human prostate cancer diagnosis.
    Krishnan S; Kanthaje S; Punchappady DR; Mujeeburahiman M; Ratnacaram CK
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):951-967. PubMed ID: 35764700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate Cancer (PCa) Status.
    Snider AJ; Seeds MC; Johnstone L; Snider JM; Hallmark B; Dutta R; Moraga Franco C; Parks JS; Bensen JT; Broeckling CD; Mohler JL; Smith GJ; Fontham ETH; Lin HK; Bresette W; Sergeant S; Chilton FH
    Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33007922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer.
    Drago D; Andolfo A; Mosca E; Orro A; Nocera L; Cucchiara V; Bellone M; Montorsi F; Briganti A
    Cancer Biol Med; 2021 May; 18(2):604-15. PubMed ID: 34037347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer.
    Zheng H; Dong B; Ning J; Shao X; Zhao L; Jiang Q; Ji H; Cai A; Xue W; Gao H
    Clin Chim Acta; 2020 Feb; 501():241-251. PubMed ID: 31758937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
    Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
    Front Oncol; 2021; 11():730638. PubMed ID: 34722271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.
    Pérez-Rambla C; Puchades-Carrasco L; García-Flores M; Rubio-Briones J; López-Guerrero JA; Pineda-Lucena A
    Metabolomics; 2017; 13(5):52. PubMed ID: 28804274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Metabolomics and Lipidomics Profiling of Prostate Cancer Tissue Reveals Metabolic Dysregulations Associated with Disease Development.
    Lima AR; Carvalho M; Aveiro SS; Melo T; Domingues MR; Macedo-Silva C; Coimbra N; Jerónimo C; Henrique R; Bastos ML; Guedes de Pinho P; Pinto J
    J Proteome Res; 2022 Mar; 21(3):727-739. PubMed ID: 34813334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in proteomic prostate cancer biomarker discovery.
    Goo YA; Goodlett DR
    J Proteomics; 2010 Sep; 73(10):1839-50. PubMed ID: 20398807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive Serum Metabolomic Profiling Reveals Elevated Kynurenine Pathway's Metabolites in Humans with Prostate Cancer.
    Khan A; Choi SA; Na J; Pamungkas AD; Jung KJ; Jee SH; Park YH
    J Proteome Res; 2019 Apr; 18(4):1532-1541. PubMed ID: 30628444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer.
    Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS
    Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
    Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.
    Markin PA; Brito A; Moskaleva N; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; La Frano MR; Appolonova SA
    Metabolomics; 2020 Jun; 16(7):74. PubMed ID: 32556743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current advances of liquid biopsies in prostate cancer: Molecular biomarkers.
    Alahdal M; Perera RA; Moschovas MC; Patel V; Perera RJ
    Mol Ther Oncolytics; 2023 Sep; 30():27-38. PubMed ID: 37575217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GC-MS-Based Endometabolome Analysis Differentiates Prostate Cancer from Normal Prostate Cells.
    Lima AR; Araújo AM; Pinto J; Jerónimo C; Henrique R; Bastos ML; Carvalho M; Guedes de Pinho P
    Metabolites; 2018 Mar; 8(1):. PubMed ID: 29562689
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.